Decrease in tetrahydrobiopterin as a possible cause of nephropathy in type II diabetic rats

Kidney International

Volumn 70, Issue 3, 2006, Pages 471-476

  Okumura, M ^a   Masada, M ^b   Yoshida, Y ^b   Shintaku, H ^c   Hosoi, M ^a   Okada, N ^a   Konishi, Y ^a   Morikawa, T ^a   Miura, K ^c   Imanishi, M ^a  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Benidipine; Biopterin; GTP cyclohydrolase I

Indexed keywords

BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CARBOXYMETHYLCELLULOSE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN; TETRAHYDROBIOPTERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE MODEL; DOSE TIME EFFECT RELATION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; KIDNEY BLOOD FLOW; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION;

ANIMALS; BIOPTERIN; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CALCIUM CHANNEL BLOCKERS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIHYDROPYRIDINES; KIDNEY; MALE; NITRIC OXIDE; PROTEINURIA; RATS; RATS, INBRED OLETF; RATS, LONG-EVANS;

EID: 33746540481     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000431     Document Type: Article

References (44)

1. Kone BC, Baylis C. Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol 1997; 272: F561-F578.
2. Persson PB. Nitric oxide in the kidney. Am J Physiol Regul Integr Comp Physiol 2002; 283: R1005-R1007.
3. Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 2003; 284: F1121-F1137.
4. Keynan S, Hirshberg B, Levin-Iaina N et al. Renal nitric oxide production during the early phase of experimental diabetes mellitus. Kidney Int 2000; 58: 740-747.
5. Prabhakar SS. Role of nitric oxide in diabetic nephropathy. Semin Nephrol 2004; 24: 333-344.
6. Stuehr DJ. Structure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol 1997; 37: 339-359.
7. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593-615.
8. Landmesser U, Dikalov S, Price SR et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-1209.
9. 2-imbalance in insulin-resistant rat aorta. Diabetes 1999; 48: 2437-2445.
10. Meininger CJ, Marinos RS, Hatakeyama K et al. Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem J 2000; 349: 353-356.
11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.
12. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-720.
13. Imanishi M, Yoshioka K, Konishi Y et al. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia 1999; 42: 999-1005.
14. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15: 1983-1992.
15. Ding Y, Vaziri ND. Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension 1998; 32: 718-723.
16. Kobayashi N, Kobayashi K, Hara K et al. Benidipine stimulates nitric oxide synthase and improves coronary circulation in hypertensive rats. Am J Hypertens 1999; 12: 483-491.
17. Kitakaze M, Node K, Minamino T et al. A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol 1999; 33: 242-249.
18. Kawano K, Hirashima T, Mori S et al. Spontaneous long-term hyperglycemic rat with diabetic complications, Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41: 1422-1428.
19. Kone BC. Nitric oxide synthesis in the kidney: isoforms, biosynthesis, and functions in health. Semin Nephrol 2004; 24: 299-315.
20. Pacher P, Obrosova IG, Mabley JG, Szabo C. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 2005; 12: 267-275.
21. Chander PN, Gealekman O, Brodsky SV et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 2004; 15: 2391-2403.
22. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 1998; 31: 1047-1060.
23. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol 1997; 29: 8-15.
24. Shinozaki K, Nishio Y, Okamura T et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 2000; 87: 566-573.
25. Hamon CG, Cutler P, Blair JA. Tetrahydrobiopterin metabolism in the streptozotocin induced diabetic state in rats. Clin Chim Acta 1989; 181: 249-253.
26. Erdely A, Freshour G, Maddox DA et al. Renal disease in rats with type 2 diabetes is associated with decreased renal nitric oxide production. Diabetologia 2004; 47: 1672-1676.
27. Craven PA, DeRubertis FR, Melhem M. Nitric oxide in diabetic nephropathy. Kidney Int Suppl 1997; 60: S46-S53.
28. Wessels J, Peake P, Pussell BA, Macdonald GJ. Nitric oxide synthase inhibition in a spontaneously hypertensive rat model of diabetic nephropathy. Clin Exp Pharmacol Physiol 1997; 24: 451-453.
29. Wever RM, Luscher TF, Cosentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112.
30. Cosentino F, Patton S, d'Uscio LV et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998; 101: 1530-1537.
31. Komori Y, Hyun J, Chiang K, Fukuto JM. The role of thiols in the apparent activation of rat brain nitric oxide synthase (NOS). J Biochem (Tokyo) 1995; 117: 923-927.
32. Viveros OH, Lee CL, Abou-Donia MM et al. Biopterin cofactor biosynthesis: independent regulation of GTP cyclohydrolase in adrenal medulla and cortex. Science 1981; 213: 349-350.
33. Hwang O, Choi HJ, Park SY. Up-regulation of GTP cyclohydrolase I and tetrahydrobiopterin by calcium influx. NeuroReport 1999; 10: 3611-3614.
34. Salameh A, Schomecker G, Breitkopf K et al. The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells. Br J Pharmacol 1996; 118: 1899-1904.
35. Taddei S, Virdis A, Ghiadoni L et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001; 37: 943-948.
36. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97: 576-580.
37. Brovkovych VV, Kalinowski L, Muller-Peddinghaus R, Malinski T. Synergistic antihypertensive effects of nifedipine on endothelium: concurrent release of NO and scavenging of superoxide. Hypertension 2001; 37: 34-39.
38. Jesmin S, Sakuma I, Hattori Y et al. Long-acting calcium channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodelling in a Type II diabetic rat model. Diabetologia 2002; 45: 402-415.
39. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
40. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
41. Higashiura K, Ura N, Takada T et al. Alteration of muscle fiber composition linking to insulin resistance and hypertension in fructose-fed rats. Am J Hypertens 1999; 12: 596-602.
42. Masada M, Akino M, Sueoka T, Katoh S. Dyspropterin, an intermediate formed from dihydroneopterin triphosphate in the biosynthetic pathway of tetrahydrobiopterin. Biochim Biophys Acta 1985; 840: 235-244.
43. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984; 26: 137-143.
44. Okumura M, Imanishi M, Okamura M et al. Role for thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats. Life Sci 2003; 72: 2695-2705.